Cadila Healthcare has divested its entire shareholding in Bremer Pharma GmbH, Germany, a wholly owned subsidiary of the company and consequently, Bremer ceased to be a subsidiary of the company. The company received consideration at enterprise value of Euro 2,263,431 of which share sale value is Euro 827,344 and loan value (extended by Zydus International - a wholly owned subsidiary of the company) is Euro 1,436,087. – Business Standard

10 Diagnostic Imaging Trends for 2018



Digital version